JDP2

Summary

JDP2 (Jun dimerization protein 2, HGNC:17546) is a protein-coding gene on chromosome 14q24.3, encoding Jun dimerization protein 2 (Q8WYK2). Component of the AP-1 transcription factor that represses transactivation mediated by the Jun family of proteins.

Enables DNA-binding transcription repressor activity, RNA polymerase II-specific and sequence-specific double-stranded DNA binding activity. Involved in negative regulation of transcription by RNA polymerase II. Located in nucleus. Part of RNA polymerase II transcription regulator complex.

Source: NCBI Gene 122953 — RefSeq curated summary.

At a glance

• GWAS associations: 8
• Clinical variants (ClinVar): 43 total
• Transcription factor: yes — 36 downstream targets (CollecTRI)
• MANE Select transcript: NM_001135048

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17546
Approved symbol	JDP2
Name	Jun dimerization protein 2
Location	14q24.3
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000140044
Ensembl biotype	protein_coding
OMIM	608657
Entrez	122953

Gene structure

Transcript identifiers

Ensembl transcripts: 17 — 15 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000267569, ENST00000419727, ENST00000435893, ENST00000437176, ENST00000558068, ENST00000559060, ENST00000559773, ENST00000651602, ENST00000879974, ENST00000879975, ENST00000924615, ENST00000924616, ENST00000924617, ENST00000955938, ENST00000955939, ENST00000955940, ENST00000955941

RefSeq mRNA: 4 — MANE Select: NM_001135048 NM_001135047, NM_001135048, NM_001135049, NM_130469

CCDS: CCDS45139, CCDS9842

Canonical transcript exons

ENST00000651602 — 4 exons

Exon	Start	End
ENSE00003636904	75437898	75438121
ENSE00003847511	75428022	75428252
ENSE00003849504	75469290	75474107
ENSE00003895338	75461426	75461530

Expression profiles

Bgee: expression breadth ubiquitous, 244 present calls, max score 97.52.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 33.9435 / max 847.8642, expressed in 1734 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
140667	32.6349	1727
140666	0.6612	252
140669	0.6411	345
140668	0.0063	2

Top tissues by expression

256 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
synovial joint	UBERON:0002217	97.52	gold quality
cardiac muscle of right atrium	UBERON:0003379	96.95	silver quality
layer of synovial tissue	UBERON:0007616	96.80	gold quality
upper arm skin	UBERON:0004263	96.67	silver quality
calcaneal tendon	UBERON:0003701	96.32	gold quality
vena cava	UBERON:0004087	95.83	gold quality
sural nerve	UBERON:0015488	95.62	gold quality
kidney epithelium	UBERON:0004819	95.31	silver quality
decidua	UBERON:0002450	95.18	gold quality
lower lobe of lung	UBERON:0008949	95.15	gold quality
left ventricle myocardium	UBERON:0006566	95.09	silver quality
ileal mucosa	UBERON:0000331	94.95	gold quality
right lung	UBERON:0002167	94.83	gold quality
saphenous vein	UBERON:0007318	94.81	gold quality
monocyte	CL:0000576	94.64	gold quality
spleen	UBERON:0002106	94.15	gold quality
leukocyte	CL:0000738	94.02	gold quality
trachea	UBERON:0003126	93.84	gold quality
omental fat pad	UBERON:0010414	93.67	gold quality
peritoneum	UBERON:0002358	93.64	gold quality
upper lobe of lung	UBERON:0008948	93.26	gold quality
upper lobe of left lung	UBERON:0008952	93.23	gold quality
adipose tissue of abdominal region	UBERON:0007808	93.05	gold quality
mucosa of stomach	UBERON:0001199	92.70	gold quality
epithelial cell of pancreas	CL:0000083	92.63	silver quality
tibial nerve	UBERON:0001323	92.48	gold quality
mucosa of paranasal sinus	UBERON:0005030	92.47	gold quality
subcutaneous adipose tissue	UBERON:0002190	92.16	gold quality
gall bladder	UBERON:0002110	92.15	gold quality
dorsal root ganglion	UBERON:0000044	92.08	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	11.90

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

36 targets.

Target	Regulation
ACP5
APEH
ATF2
ATF3	Repression
CARM1
CASR
CCNA2	Unknown
CCND1	Repression
CD40
CDKN2A	Activation
CDKN2B
CEBPD	Repression
CREBBP
CSF1R
CTSK	Activation
DDIT3	Repression
IGBP1
IGFBP7
JUN
KAT2B
LGALS1
MEST
MT1A
NFKB
NOTCH1
PLXNA2
PLXNB2
POLI
POMC
PON2

JASPAR motifs

Motif	Name	Family
MA0655.1	JDP2	Fos-related
MA0656.1	JDP2	Fos-related
MA0656.2	JDP2	Fos-related

JASPAR matrix evidence (PMIDs): PMID:9154808

Upstream regulators (CollecTRI, top): NANOG, SPI1, TBX3, TP53

miRNA regulators (miRDB)

83 targeting JDP2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5193	100.00	67.26	1744
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-568	99.98	69.86	2084
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-101-3P	99.94	75.03	2230
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-1236-3P	99.94	68.04	1695
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-3119	99.92	71.34	2390
HSA-MIR-3686	99.90	70.53	2432
HSA-MIR-8062	99.88	68.43	995
HSA-MIR-129-5P	99.88	70.26	3273
HSA-LET-7A-2-3P	99.87	70.53	1921
HSA-MIR-221-5P	99.86	65.45	1052
HSA-MIR-8073	99.86	65.21	1118
HSA-LET-7G-3P	99.85	70.43	1929
HSA-MIR-765	99.84	68.24	2442
HSA-MIR-4679	99.76	69.19	1229

Literature-anchored findings (GeneRIF, showing 19)

• c-Jun dimerization protein 2 inhibits cell transformation and has a role as a tumor suppressor gene (PMID:14627710)
• JDP2 is a cellular survival protein whose presence is necessary for normal cellular function (PMID:16026868)
• JDP2 acts as a repressor and could be functionally associated with HDAC3 to inhibit CHOP transcription (PMID:18396163)
• IRF2-BP1 is a JDP2-binding protein enhancing the polyubiquitination of JDP2 and represses ATF2-mediated transcriptional activation from a CRE-containing promoter. (PMID:18671972)
• A progesterone receptor co-activator (JDP2) mediates activity through interaction with residues in the carboxyl-terminal extension of the DNA binding domain. (PMID:19553667)
• 3 SNPs (2 intronic: rs741846 & rs175646; & 1 in the untranslated region: rs8215) & their genotype distribution showed significant association in the Japanese & Korean but not Dutch intracranial aneurysm patients. (PMID:20452405)
• JDP2 expression was downregulated in pancreatic carcinoma & this correlated with metastasis & decreased post-surgery survival. (PMID:20677166)
• The molecular mechanisms that underlie the action of JDP2 in cellular aging and replicative senescence by mediating the dissociation of polycomb repressive complexes from the p16(Ink4a)/Arf locus are discussed. (PMID:20950777)
• JDP2 is crucial to triggering reactivation from latency to lytic replication (PMID:21525011)
• the recruitment of multiple HDAC members to JDP2 and ATF3 is part of their transcription repression mechanism. (PMID:22989952)
• Preeclamptic plasma induces transcription modifications involving the AP-1 transcriptional regulator JDP2 in endothelial cells. (PMID:24120378)
• Results suggest that JDP2 is an integral component of the Nrf2-MafK complex and that it modulates antioxidant and detoxification programs by acting via the ARE. (PMID:24232097)
• In hepatocellular carcinoma, high expression of JDP2 is significantly correlated with smaller tumor size, early stage HCC and better survival. (PMID:28315425)
• These studies establish JDP2 as a novel oncogene in high-risk T cell acute lymphoblastic leukemia. (PMID:29941549)
• JDP2 was downregulated in myelodysplastic syndrome. Its expression was inversely related to disease aggressiveness and AML transformation. JDP2 suppression is a direct result of reduced PU.1. PU.1 and JDP2 expression correlate and are concurrently reduced with the extent of differentiation arrest and aggression/prognosis in MDS/AML. It was upregulated upon azacytidine treatment. (PMID:30721335)
• JDP2 is downregulated in HCC tissues and cells, and overexpressed JDP2 facilitated HCC cell invasion and EMT. (PMID:30877624)
• Down-regulated lncRNA AGAP2-AS1 contributes to pre-eclampsia as a competing endogenous RNA for JDP2 by impairing trophoblastic phenotype. (PMID:32150333)
• JDP2 is directly regulated by ATF4 and modulates TRAIL sensitivity by suppressing the ATF4-DR5 axis. (PMID:33108704)
• Palmitic acid-induced microRNA-143-5p expression promotes the epithelial-mesenchymal transition of retinal pigment epithelium via negatively regulating JDP2. (PMID:37179125)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	jdp2b	ENSDARG00000020133
danio_rerio	jdp2a	ENSDARG00000040137
mus_musculus	Jdp2	ENSMUSG00000034271
rattus_norvegicus	Jdp2	ENSRNOG00000063964
drosophila_melanogaster	Atf3	FBGN0028550

Paralogs (8): FOSL2 (ENSG00000075426), BATF3 (ENSG00000123685), FOSB (ENSG00000125740), BATF (ENSG00000156127), ATF3 (ENSG00000162772), BATF2 (ENSG00000168062), FOS (ENSG00000170345), FOSL1 (ENSG00000175592)

Protein

Protein identifiers

Jun dimerization protein 2 — Q8WYK2 (reviewed: Q8WYK2)

All UniProt accessions (2): Q8WYK2, H0YKE4

UniProt curated annotations — full annotation on UniProt →

Function. Component of the AP-1 transcription factor that represses transactivation mediated by the Jun family of proteins. Involved in a variety of transcriptional responses associated with AP-1 such as UV-induced apoptosis, cell differentiation, tumorigenesis and antitumogeneris. Can also function as a repressor by recruiting histone deacetylase 3/HDAC3 to the promoter region of JUN. May control transcription via direct regulation of the modification of histones and the assembly of chromatin.

Subunit / interactions. Forms a homodimer or heterodimer with JUN, JUNB, JUND, CEBPG and ATF2 thereby inhibiting transactivation by JUN, ATF2 and CEBPG. Binds multiple DNA elements such as cAMP-response element (CRE) and TPA response element (TRE) either as homodimer or heterodimer. Interacts with IRF2BP1.

Subcellular location. Nucleus.

Post-translational modifications. Phosphorylation of Thr-148 by MAPK8 in response to different stress conditions such as, UV irradiation, oxidatives stress and anisomycin treatments. Polyubiquitinated; probably by IRF2BP1.

Similarity. Belongs to the bZIP family. ATF subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8WYK2-1	1	yes
Q8WYK2-2	2

RefSeq proteins (4): NP_001128519, NP_001128520, NP_001128521, NP_569736 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000837	AP-1	Family
IPR004827	bZIP	Domain
IPR046347	bZIP_sf	Homologous_superfamily

Pfam: PF00170

UniProt features (10 total): region of interest 4, chain 1, domain 1, modified residue 1, cross-link 1, splice variant 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8WYK2-F1	76.36	0.42

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 148, 65

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 197 (showing top): GSE45365_NK_CELL_VS_CD11B_DC_DN, GSE45365_NK_CELL_VS_BCELL_UP, GSE18804_SPLEEN_MACROPHAGE_VS_COLON_TUMORAL_MACROPHAGE_UP, GOBP_REGULATION_OF_FAT_CELL_DIFFERENTIATION, WWTAAGGC_UNKNOWN, GOBP_NEGATIVE_REGULATION_OF_FAT_CELL_DIFFERENTIATION, NKX25_02, SHEPARD_CRASH_AND_BURN_MUTANT_UP, AAGCCAT_MIR135A_MIR135B, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, LHX3_01, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_1, chr14q24, FOSTER_TOLERANT_MACROPHAGE_UP, NF1_Q6_01

GO Biological Process (6): negative regulation of transcription by RNA polymerase II (GO:0000122), chromatin remodeling (GO:0006338), regulation of transcription by RNA polymerase II (GO:0006357), fat cell differentiation (GO:0045444), negative regulation of fat cell differentiation (GO:0045599), regulation of DNA-templated transcription (GO:0006355)

GO Molecular Function (14): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA-binding transcription repressor activity, RNA polymerase II-specific (GO:0001227), chromatin binding (GO:0003682), cAMP response element binding (GO:0035497), protein homodimerization activity (GO:0042803), histone deacetylase binding (GO:0042826), leucine zipper domain binding (GO:0043522), protein heterodimerization activity (GO:0046982), histone chaperone activity (GO:0140713), sequence-specific double-stranded DNA binding (GO:1990837), DNA binding (GO:0003677), DNA-binding transcription factor activity (GO:0003700), protein binding (GO:0005515)

GO Cellular Component (3): chromatin (GO:0000785), nucleus (GO:0005634), RNA polymerase II transcription regulator complex (GO:0090575)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA polymerase II transcription regulatory region sequence-specific DNA binding	3
regulation of transcription by RNA polymerase II	2
transcription by RNA polymerase II	2
regulation of DNA-templated transcription	2
binding	2
protein dimerization activity	2
negative regulation of DNA-templated transcription	1
chromatin organization	1
cell differentiation	1
fat cell differentiation	1
negative regulation of cell differentiation	1
regulation of fat cell differentiation	1
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
negative regulation of transcription by RNA polymerase II	1
DNA-binding transcription factor activity, RNA polymerase II-specific	1
DNA-binding transcription repressor activity	1
RNA polymerase II cis-regulatory region sequence-specific DNA binding	1
identical protein binding	1
enzyme binding	1
LRR domain binding	1
histone binding	1
protein carrier activity	1
double-stranded DNA binding	1
sequence-specific DNA binding	1
nucleic acid binding	1
transcription cis-regulatory region binding	1
transcription regulator activity	1
chromosome	1
cellular anatomical structure	1
intracellular membrane-bounded organelle	1
transcription regulator complex	1
nuclear protein-containing complex	1

Protein interactions and networks

STRING

1238 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
JDP2	JUND	P17535	932
JDP2	ARL4C	P56559	905
JDP2	JUN	P05412	891
JDP2	JUNB	P17275	849
JDP2	CEBPG	P53567	768
JDP2	BATF	Q16520	747
JDP2	ATF3	P18847	698
JDP2	FOS	P01100	697
JDP2	CTSK	P43235	657
JDP2	HDAC3	O15379	623
JDP2	FOSL2	P15408	607
JDP2	MAF	O75444	606
JDP2	EP300	Q09472	528
JDP2	DDIT3	P35638	527
JDP2	ATF7	P17544	516

IntAct

27 interactions, top by confidence:

A	B	Type	Score
JUN	ATF2	psi-mi:“MI:0914”(association)	0.950
JDP2	JUN	psi-mi:“MI:0914”(association)	0.690
JUN	NFATC1	psi-mi:“MI:0914”(association)	0.610
Atf2	JDP2	psi-mi:“MI:0407”(direct interaction)	0.590
Atf2	JDP2	psi-mi:“MI:0915”(physical association)	0.590
JDP2	IRF2BP1	psi-mi:“MI:0915”(physical association)	0.580
ATF4	JDP2	psi-mi:“MI:0915”(physical association)	0.560
CREB5	JDP2	psi-mi:“MI:0915”(physical association)	0.560
DDIT3	JDP2	psi-mi:“MI:0915”(physical association)	0.560
ATF2	JDP2	psi-mi:“MI:0915”(physical association)	0.550
JUNB	JDP2	psi-mi:“MI:0915”(physical association)	0.550
JDP2	JUNB	psi-mi:“MI:0914”(association)	0.550
JUN	NKRF	psi-mi:“MI:0914”(association)	0.460
JDP2	PGR	psi-mi:“MI:0915”(physical association)	0.400
	JDP2	psi-mi:“MI:0915”(physical association)	0.370
GTF2H1	JDP2	psi-mi:“MI:0915”(physical association)	0.370
JUN		psi-mi:“MI:0914”(association)	0.350
JDP2	RPLP0	psi-mi:“MI:0914”(association)	0.350
JDP2	DDIT3	psi-mi:“MI:0915”(physical association)	0.000
JDP2	ATF4	psi-mi:“MI:0915”(physical association)	0.000
JDP2	CREB5	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (34): JDP2 (Affinity Capture-MS), JDP2 (Affinity Capture-RNA), JDP2 (Affinity Capture-MS), JDP2 (Affinity Capture-MS), JDP2 (Biochemical Activity), JDP2 (Two-hybrid), CREB5 (Two-hybrid), DDIT3 (Two-hybrid), TP53 (Reconstituted Complex), JDP2 (Affinity Capture-RNA), IRF2BP1 (Affinity Capture-Western), ATF7 (Affinity Capture-Western), JUND (Affinity Capture-Western), JUN (Affinity Capture-Western), JDP2 (Affinity Capture-Western)

ESM2 similar proteins: A4IGK3, B7ZAP0, O08609, O54941, O55047, O60519, P18847, P26801, P28574, P29596, P37285, P52161, P52162, P52164, P60762, P61244, P61245, P97875, Q07016, Q07866, Q08CW1, Q08DJ0, Q0VCP9, Q0VD32, Q13330, Q28772, Q2KII1, Q32KT0, Q32M00, Q3T0B9, Q56A18, Q5BJU6, Q5R581, Q5ZIL4, Q60765, Q62599, Q642H2, Q6PH81, Q78E65, Q7TMY4

Diamond homologs: A1L2X1, D4A7E1, E1BD44, F1QW76, F7EMX9, O02761, O35284, O77628, O88479, O97930, P01100, P01101, P01102, P11939, P12841, P18847, P23050, P29176, P29596, P53450, Q16520, Q2KII1, Q56TN0, Q56TT7, Q60765, Q6DGM8, Q8HZP6, Q8N1L9, Q8WYK2, Q91496, Q9Z2Q8, A8MPH9, B3MTI9, B3P5D2, B4G652, B4HZE8, B4JYN3, B4K617, B4M5T7, B4PPK2

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
JDP2	“down-regulates activity”	ATF2	binding
JDP2	“down-regulates activity”	JUN	binding
MAPK14	unknown	JDP2	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

43 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	30
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1075 predictions. Top by Δscore:

Variant	Effect	Δscore
14:75438117:GTGAG:G	donor_gain	1.0000
14:75461422:ACAG:A	acceptor_loss	1.0000
14:75461424:A:AG	acceptor_gain	1.0000
14:75461424:AGCT:A	acceptor_loss	1.0000
14:75461425:G:GA	acceptor_gain	1.0000
14:75461425:GCT:G	acceptor_gain	1.0000
14:75461425:GCTA:G	acceptor_gain	1.0000
14:75461527:GCGG:G	donor_gain	1.0000
14:75469285:TACA:T	acceptor_loss	1.0000
14:75469287:CA:C	acceptor_loss	1.0000
14:75469288:A:AG	acceptor_gain	1.0000
14:75469288:AG:A	acceptor_gain	1.0000
14:75469289:G:GA	acceptor_loss	1.0000
14:75469289:G:GG	acceptor_gain	1.0000
14:75469289:GG:G	acceptor_gain	1.0000
14:75469289:GGA:G	acceptor_gain	1.0000
14:75437896:A:AG	acceptor_gain	0.9900
14:75437896:AGGCT:A	acceptor_gain	0.9900
14:75437897:G:GG	acceptor_gain	0.9900
14:75437897:GGCT:G	acceptor_gain	0.9900
14:75437897:GGCTG:G	acceptor_gain	0.9900
14:75438120:AGGT:A	donor_loss	0.9900
14:75438121:GGTGA:G	donor_loss	0.9900
14:75438122:G:A	donor_loss	0.9900
14:75461422:A:AG	acceptor_gain	0.9900
14:75461423:C:G	acceptor_gain	0.9900
14:75461425:GC:G	acceptor_gain	0.9900
14:75461529:GG:G	donor_gain	0.9900
14:75461530:GG:G	donor_gain	0.9900
14:75461531:G:GG	donor_gain	0.9900

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000083125 (14:75469972 C>T), RS1000120623 (14:75439871 G>A,T), RS1000162992 (14:75427889 C>G,T), RS1000202338 (14:75447681 T>C), RS1000235926 (14:75453217 T>C,G), RS1000300997 (14:75467238 T>C), RS1000311588 (14:75433526 T>A,G), RS1000341896 (14:75433787 C>T), RS1000344294 (14:75442052 G>C), RS1000421513 (14:75439565 T>C), RS1000461192 (14:75455662 C>T), RS1000463197 (14:75470013 C>T), RS1000554058 (14:75455246 C>G), RS1000560494 (14:75452015 C>A), RS1000651320 (14:75452209 T>G)

Disease associations

OMIM: gene MIM:608657 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

8 associations (top):

Study	Trait	p-value
GCST001588_6	Periodontal microbiota	9.000000e-07
GCST001762_510	Obesity-related traits	7.000000e-06
GCST005038_87	Allergic disease (asthma, hay fever or eczema)	9.000000e-09
GCST005531_81	Multiple sclerosis	2.000000e-07
GCST008870_13	Keratinocyte cancer (MTAG)	2.000000e-08
GCST008871_45	Basal cell carcinoma	5.000000e-10
GCST90000025_544	Appendicular lean mass	6.000000e-16
GCST90013410_52	Basal cell carcinoma	4.000000e-09

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0010176	keratinocyte carcinoma
EFO:0004980	appendicular lean mass

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

68 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression	4
Cyclosporine	increases expression	3
bisphenol A	decreases methylation, affects cotreatment, increases expression	2
sodium arsenite	decreases expression, increases expression	2
entinostat	increases expression, affects cotreatment	2
bisphenol S	decreases methylation, affects cotreatment, increases expression	2
Panobinostat	affects cotreatment, increases expression	2
Air Pollutants	decreases expression, affects expression, increases abundance	2
Benzo(a)pyrene	decreases expression	2
Tetrachlorodibenzodioxin	affects expression	2
Tobacco Smoke Pollution	decreases expression, increases expression	2
Aflatoxin B1	affects expression, decreases expression	2
p-Chloromercuribenzoic Acid	affects cotreatment, increases expression	2
Particulate Matter	decreases expression, decreases reaction, increases abundance	2
aristolochic acid I	decreases expression	1
bisphenol F	affects cotreatment, increases expression	1
methylmercuric chloride	increases expression	1
triphenyl phosphate	affects expression	1
arsenite	affects binding, increases reaction	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
benzo(e)pyrene	decreases methylation	1
ferrous chloride	decreases expression	1
cupric oxide	increases expression	1
resorcinol	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	increases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
ICG 001	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.